Mirtazapine Teva

Mirtazapine, the active ingredient in Mirtazapine Teva, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirtazapine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine Teva is a NaSSA antidepressant that acts on central neurotransmitter pathways to improve mood in depressive disorders.

- Major depressive disorder: alleviates depressive symptoms and improves functional outcomes in adults.

Mirtazapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Suicidal thoughts or behavior - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Hepatic dysfunction - Orthostatic hypotension

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Hepatic function: assess liver enzymes in patients with hepatic impairment. - Weight monitoring: track body weight due to possible increase. - Elderly patients: start at lower doses and monitor for sedation. - Discontinuation: avoid abrupt cessation to reduce withdrawal symptoms. - Pregnancy and lactation: consider risk‑benefit ratio; use only if clearly needed. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes; careful review of concomitant medications is essential.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome. - Carbamazepine: induces metabolism, reducing efficacy. - Fluoxetine or other CYP2D6 inhibitors: may increase mirtazapine levels. - Alcohol: enhances sedative effects.

Moderate Interactions (Monitor Closely): - Antihistamines: additive sedation. - Benzodiazepines: increased central nervous system depression. - Warfarin: possible alteration of INR. - NSAIDs: heightened risk of gastrointestinal bleeding. - Antihypertensives: may potentiate blood pressure lowering.